Direct oral administration via drinking water represents the largest-volume downstream use for live yak paratyphoid vaccine API when whole-herd vaccination is required without individual animal handling. The lyophilized bacterial biomass is blended with 15–25% w/w trehalose dihydrate, 8–12% w/w potassium phosphate buffer salts adjusted to pH 7.0–7.4, 2–4% w/w sodium glutamate, and 1–2% w/w hydrolyzed gelatin before being filled into foil-laminated polyethylene terephthalate sachets under nitrogen at ≤30% RH. Terminal powder moisture is held below 2.0% by Karl Fischer titration. Prior to administration, the powder is reconstituted in non-chlorinated water at 15–22°C; residual free chlorine must be <0.1 mg/L, and water pH should remain between 6.8 and 7.4 to avoid envelope damage to the live bacterial cells. The reconstituted suspension is targeted at 1×10⁷ CFU/mL, with a consumption window of 2 h to limit thermal and osmotic viability loss. Production-scale blending is conducted in a V-cone blender at 15 rpm for 20 min; longer mixing times provide no additional homogeneity and can increase shear exposure. Microbiological quality is evaluated according to Ph. Eur. 2.6.13 and Ph. Eur. 5.1.4, while suspension preparation for enumeration follows ISO 6887-1. Published field titration data for the yak-specific paratyphoid serovar in this powder format is limited; the stated CFU targets reflect compendial live bacterial vaccine practice rather than a confirmed minimum protective dose. Terminal use is as a water-dispersible powder for oral vaccination in yak herds, with chlorine, copper ions, cationic disinfectants, and ultraviolet exposure identified as the principal incompatibilities.

Injectable Suspension Stability When Live Bacterial API Enters a Phosphate-Buffered Aseptic Fill Line

For parenteral immunization, the live yak paratyphoid API is formulated as a suspension in 10 mM phosphate-buffered saline at pH 7.2, supplemented with 0.5% w/v hydrolyzed gelatin and 2.0% w/v sucrose as extracellular cryoprotectants and viscosity modifiers. The target bacterial load is 1×10⁸ CFU/mL, filled as a 2 mL dose into Type I glass vials sealed with bromobutyl rubber stoppers. The phosphate-buffered diluent is sterilized through a 0.22 µm polyethersulfone membrane, but the live API cannot be sterile-filtered and is therefore blended aseptically in an ISO 14644-1 Class 5 isolator with unidirectional airflow. Filling line speed is maintained at ≤60 vials/min, and peristaltic pump line pressure is kept below 0.2 bar to reduce shear-induced loss of bacterial viability. Terminal product is a 10-dose vial stored at 2–8°C. Batch release testing includes extraneous agent detection under current Ph. Eur. monograph 0062, bacterial endotoxin evaluation by Ph. Eur. 2.6.14 with a limit of <0.5 EU/dose, and uniformity of delivered volume according to Ph. Eur. 2.9.1 and 2.9.40. Oil-in-water adjuvants, residual ethylene oxide, and cationic surfactants are incompatible with this live bacterial suspension because they reduce viability or destabilize the cellular membrane. The injection route is reserved for controlled vaccination campaigns where precise per-animal dosing and immediate immune exposure justify the narrower thermal stability envelope.

Oral capsule dosage forms demand a non-aqueous fill matrix because the lyophilized yak paratyphoid API loses viability rapidly above 2.0% moisture and in the presence of free water. The API is blended with anhydrous lactose monohydrate at 60–70% w/w, microcrystalline cellulose at 20–30% w/w, croscarmellose sodium at 2–3% w/w, and magnesium stearate at 0.5% w/w. The powder is filled into size 1 hard HPMC capsules at ≤25°C and ≤30% RH; the target fill weight is 250 mg, delivering 1×10⁹ CFU per capsule. Enteric coating is applied using an aqueous dispersion of Eudragit L100-55 at 20% w/w solids, with triethyl citrate at 10% w/w of polymer and talc at 50% w/w of polymer. Coating pan inlet air is held at 45–50°C while product temperature is controlled at ≤30°C to avoid thermal inactivation; a weight gain of 7–10% is applied. Disintegration testing according to Ph. Eur. 2.9.1 requires no release in 0.1 M HCl for 2 h, followed by complete release in phosphate buffer pH 6.8 within 45 min. Content uniformity is assessed by Ph. Eur. 2.9.40, and microbiological quality is controlled under Ph. Eur. 5.1.4. Published formulation-specific viability recovery data for this exact yak paratyphoid capsule configuration is limited; a post-encapsulation recovery target of ≥80% relative to input CFU is applied as an internal release criterion. Terminal use is an acid-resistant oral capsule for neonatal yak calves, with moisture ingress and aqueous coating processes identified as critical process risks.

What Limits Tablet Compression Force for Lyophilized Bacterial Antigen Blends?

When direct compression is selected for tablet delivery, the compression force must remain within a narrow band because the live yak paratyphoid API is shear-sensitive and cannot tolerate excessive mechanical stress. The direct-compression blend consists of spray-dried mannitol at 75–80% w/w, trehalose dihydrate at 5–10% w/w, crospovidone at 3–5% w/w, and sodium stearyl fumarate at 0.75–1.0% w/w. Tablets are compressed to a weight of 1.0 g, with a target dose of 1×10⁹ CFU per tablet. Rotary press compression force is limited to 6–10 kN across a 12-station press, and die temperature is maintained at ≤30°C through water-cooled punches. Tablet hardness is controlled at 30–50 N, with friability below 1.0% according to Ph. Eur. 2.9.7. Disintegration in water at 37°C must occur within 3 min per Ph. Eur. 2.9.1. Viability loss is approximately 0.2 log10 CFU at 8 kN but can exceed 1.0 log10 CFU at 15 kN; published data for this specific yak paratyphoid strain in tablet compaction is limited, but the threshold is consistent with shear-sensitive bacterial biomass behavior observed in industrial lyophilized vaccine processing. Uniformity of dosage units is verified according to Ph. Eur. 2.9.40, and non-sterile microbiological quality is assessed under Ph. Eur. 5.1.4. Relative humidity above 40% during compression and hygroscopic disintegrants are incompatible with the tableting process. Terminal use is an oral tablet for yak calves, where rapid disintegration and low mechanical stress during manufacturing are the principal formulation constraints.

Granule Production by Roller Compaction Without Aqueous Granulation

Granules for oral administration are produced by dry roller compaction to avoid aqueous granulation, which would expose the live yak paratyphoid API to moisture and thermal stress. The dry blend contains lactose monohydrate at 60–65% w/w, microcrystalline cellulose at 20–25% w/w, povidone K30 at 2–3% w/w, and colloidal silicon dioxide at 0.5% w/w. Blending is performed in a bin blender at 12 rpm for 20 min. Roller compaction is operated at a roll pressure of 4–6 MPa, roll gap of 2.0–3.0 mm, and roll speed of 3–5 rpm; ribbon density is maintained between 1.2 g/cm³ and 1.4 g/cm³. The compacted ribbon is milled through a 1.0 mm screen to produce granules with a particle-size range of 0.8–1.4 mm. Final granule moisture is held below 1.8% by Karl Fischer titration. The target potency is 1×10⁹ CFU/g of granules. Particle-size distribution is controlled by Ph. Eur. 2.9.12, uniformity of dosage units by Ph. Eur. 2.9.40, and microbiological quality by Ph. Eur. 5.1.4. Alkaline lubricants, high-humidity processing areas, and aqueous binders are incompatible with this dry granulation route. Terminal use is an oral granule that can be administered by top-dress on feed or by oral syringe, offering a mid-volume alternative between water medication and individual tablet administration.

In feed premix production, the live yak paratyphoid API is not introduced before steam pelleting or extrusion because temperatures above 60°C produce rapid viability loss. The premix is therefore restricted to top-dress or non-pelleted meal applications. The carrier system consists of defatted rice bran at 70–80% w/w, calcium carbonate at 10–15% w/w, precipitated silica at 0.5–1.0% w/w as a flow aid, and mineral oil at 1.0–2.0% w/w for dust suppression. The API is blended to a target concentration of 1×10⁷ CFU/g of premix; inclusion at 500 g per tonne of complete feed yields approximately 5×10⁶ CFU/g of finished feed. Mixing is performed in a ribbon blender filled to 60–70% of capacity, operating at 20 rpm for 10 min; blend uniformity is verified with a coefficient of variation ≤5% following ISO 6497 sampling. The terminal product is packaged in 5 kg laminated bags. Regulatory compliance for medicated feed follows Regulation (EU) 2019/4 where applicable, and microbiological quality is assessed under Ph. Eur. 5.1.4. Organic acids, formaldehyde-based feed preservatives, pelleting, extrusion, and prolonged storage above 25°C are identified incompatibilities. Terminal use is a feed premix for yak herds, particularly suited to supplemental oral vaccination when drinking-water medication is not practical.

When Freeze-Dried API Is Reconstituted as a Drench Solution for Neonatal Yak Calves

Reconstitution of the freeze-dried yak paratyphoid API as a drench solution begins with 0.85% w/v sodium chloride solution containing 0.2% w/v sodium thiosulfate as a chlorine neutralizer and 0.5% w/v hydrolyzed gelatin as a stabilizer. The target concentration is 1×10⁹ CFU per 50 mL dose. The diluent is introduced into the lyophilized vial through an 18G needle, followed by gentle swirling at <500 rpm for 30–60 s; vortexing or foaming is avoided to reduce shear damage. The reconstituted solution is held at 2–8°C and used within 4 h; at 20–25°C, the use window is shortened to 2 h. Terminal product is a ready-to-use drench solution administered orally to neonatal yak calves. Microbiological quality of the non-sterile oral liquid is controlled according to Ph. Eur. 5.1.4, with microbial enumeration by Ph. Eur. 2.6.13, and identity and extraneous agent requirements follow current Ph. Eur. monograph 0062. Residual chlorine above 0.1 mg/L, ultraviolet light, chlorhexidine residues in dosing equipment, and copper sulfate in oral administration lines are incompatible with the live bacterial suspension. Published stability data specific to this yak paratyphoid drench formulation is limited, so conservative hold times and chilled storage are applied as default operational boundaries.